NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

DexCom, Inc. (DXCM) Stock Analysis

DexCom, Inc. (DXCM) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

DXCM

$87.90

−$1.81 (−2.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare DXCM with… →

DXCM Key Statistics

As of Sep 4, 2026
Trading
Open
$88.78
Previous Close
$89.71
Day's Range
87.65–89.00
52-Week Range
54.11–92.59
Volume
2.36M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$33.17B
P/E Ratio
34.74
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
28.14
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.38
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.68
EPS (ttm)Profit attributable to each share over the last twelve months.
2.53
Financials (FY)
Revenue (FY)
$4.66B+15.60%
Net Income (FY)
$836.30M+45.14%
Profit marginThe share of revenue left as profit after all costs and taxes.
20.12%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
377.36M
1-Year Return
+8.84%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
4.84M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

DXCM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+32.44%
2025−14.66%
2024−37.33%
2023+9.58%
2022−15.64%
2021+45.23%
2020+69.02%
2019+82.59%
2018+108.75%
2017−3.87%
2016 (partial year)−34.15%

As of September 4, 2026.

DXCM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.66B$836.30M17.9%
2024$4.03B$576.20M14.3%
2023$3.62B$541.50M14.9%
2022$2.91B$341.20M11.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.66B$2.80B$911.80M$836.30M17.9%
2024$4.03B$2.44B$600.00M$576.20M14.3%
2023$3.62B$2.29B$597.70M$541.50M14.9%
2022$2.91B$1.88B$391.20M$341.20M11.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

DXCM Valuation vs Medical Devices Median

Median of 151 stocks
MetricDXCMMedical Devices medianvs median
P/E34.7426.8030% above
P/S ratio6.682.98124% above
Profit margin20.12%−1.69%21.8 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

DexCom, Inc. (DXCM) carries a market capitalisation of $33.17B. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 11,000.

DXCM last closed at $87.90 on September 4, 2026. That is −$1.81 (−2.02%) against the previous close. The 52-week range on file runs from $54.11 to $92.59. The latest close sits 62.45% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.66B. That is +15.60% against the prior fiscal year, when revenue was $4.03B. The same year closed with net income of $836.30M. That is +45.14% against the prior fiscal year. The reported profit margin is 20.12%. That is 21.8 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 2.53.

Across the 4 fiscal years on file, revenue moves from $2.91B in 2022 to $4.66B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 34.74 times earnings. That is 29.63% above the Medical Devices median of 26.8. The forward P/E on file is 28.14. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.38. The price-to-sales ratio is 6.68. On price-to-sales that is 124.29% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Beta against the wider market is reported at 1.42. Daily returns over the trailing 10 years annualize to a volatility of 48.73%. The trailing one-year price return is +8.84%. Measured over 10 years, that is +14.34% a year compounded.

Growth & Income

No dividend is on file for DXCM.

2026 is still running; the price is +32.44% year to date. The strongest complete calendar year on file is 2018 at +108.75%; the weakest is 2024 at −37.33%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

DexCom, Inc. (DXCM) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
DexCom, Inc. DXCM $33.17B 34.7
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. DexCom, Inc. trades at a P/E of 34.7.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 GEHC

GE HealthCare Technologies Inc.

$31.10B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Visit website →